News from Vectron biosolutions

Stay Up-To-Date
With The Latest Updates

June 17, 2021
Vectron closes Series A investment with Dynamk Capital
Download PDF

Vectron Biosolutions to Boost Protein Production Offering with Acquisition of Secretion Platform from T3S Technologies and $2.7M Series A Financing Round

TRONDHEIM, Norway, June 17, 2021 /PRNewswire/ -- Vectron Biosolutions, upstream experts providing expression tools and services in biomanufacturing, announced today it has raised $2.7 million in a Series A financing round led by Dynamk Capital as well as the acquisition of a bacterial secretion platform from Utah based T3S Technologies. The acquisition of T3S Technologies' secretion platform combined with Vectron's core expression technology and additional financing will significantly boost Vectron's position as a leading partner to biomanufacturers looking to reduce costs associated with the production of recombinant proteins or for solutions to advance their challenging proteins to the market.

"The acquisition of T3S' secretion platform strengthens our position as a leading provider of solutions to life science industries. High-level expression followed by true secretion of proteins comprise a paradigm shift in bacterial protein manufacture and is expected to become a future industry standard", said Trond Erik Vee Aune, CEO of Vectron Biosolutions. "We are immensely excited to be joined by Reinhard Vogt and the Dynamk team, who through their long experience and proven ability to successfully grow biomanufacturing companies, has recognized the great potential in Vectron."

Biomanufacturers are looking to reduce costs associated with the production of recombinant proteins by increasing titers and improving protein solubility.  Vectron has developed proprietary expression tools to enable robust, cost-efficient production processes for recombinant proteins in E. coli and other bacteria.  

"The T3S secretion technology together with Vectron's expression technology provides customers with a unique platform for the growing demand for microbial expression systems in order to significantly reduce cost of goods", said Reinhard Vogt, Venture Partner at Dynamk Capital.

Read More
June 17, 2021
Vectron makes changes to its Board of Directors
Download PDF

With the closing of a Series A round with Dynamk Capital, Vectron adds Reinhard Vogt and Trond Erik Vee Aune as new board members.

Read More
June 17, 2021
Vectron acquires T3S Technologies' secretion platform
Download PDF

Vectron Biosolutions to Boost Protein Production Offering with Acquisition of Secretion Platform from T3S Technologies and $2.7M Series A Financing Round.

TRONDHEIM, Norway, June 17, 2021 /PRNewswire/ -- Vectron Biosolutions, upstream experts providing expression tools and services in biomanufacturing, announced today it has raised $2.7 million in a Series A financing round led by Dynamk Capital as well as the acquisition of a bacterial secretion platform from Utah based T3S Technologies. The acquisition of T3S Technologies' secretion platform combined with Vectron's core expression technology and additional financing will significantly boost Vectron's position as a leading partner to biomanufacturers looking to reduce costs associated with the production of recombinant proteins or for solutions to advance their challenging proteins to the market.

"The acquisition of T3S' secretion platform strengthens our position as a leading provider of solutions to life science industries. High-level expression followed by true secretion of proteins comprise a paradigm shift in bacterial protein manufacture and is expected to become a future industry standard", said Trond Erik Vee Aune, CEO of Vectron Biosolutions. "We are immensely excited to be joined by Reinhard Vogt and the Dynamk team, who through their long experience and proven ability to successfully grow biomanufacturing companies, has recognized the great potential in Vectron."

Biomanufacturers are looking to reduce costs associated with the production of recombinant proteins by increasing titers and improving protein solubility.  Vectron has developed proprietary expression tools to enable robust, cost-efficient production processes for recombinant proteins in E. coli and other bacteria.  

"The T3S secretion technology together with Vectron's expression technology provides customers with a unique platform for the growing demand for microbial expression systems in order to significantly reduce cost of goods", said Reinhard Vogt, Venture Partner at Dynamk Capital.

About Vectron Biosolutions AS
Founded in 2008, Vectron Biosolutions AS supplies the life science industry with superior technologies and solutions for robust and cost-efficient production of recombinant proteins in E. coli and other bacteria through a combination of experienced life science researchers, state-of-the-art laboratory facilities, a proprietary technology platform and skillful management. Please visit vectronbiosolutions.com for more information.

About Dynamk Capital
Dynamk Capital is a growth equity and venture capital firm focused on life sciences industrials. Dynamk's investment strategy is centered on identifying companies developing disruptive technologies, tools, and services that enable the full biopharma continuum across discovery, development, and manufacturing of biotherapeutics, including cell & gene therapies, and vaccines. The Dynamk team of experienced life science entrepreneurs, investors, advisors, and subject matter experts provides capital and strategic advice to entrepreneurs commercializing innovative life science technologies.  Please visit dynamk.vc for more information.

Read More
June 22, 2020
Paper on translocation of recombinant proteins into the E. coli periplasmic space
Download PDF

Gawin, Ertesvåg, Hansen, Malmo and Brautaset has recently published a new paper on translocation of recombinant proteins into the E. coli periplasmic space.

The paper is available over open access and can be read here.

Read More
August 4, 2019
Vectron is granted new patent
Download PDF

Vectron's dual UTR technology has been granted patent protection by the European Patent Office.

This technology allows the design of synthetic 5'-UTR sequences for maximized transcription and translation, individually. A common problem when optimizing 5'-UTRs for elevated expression of recombinant proteins is that an increase in transcription negatively affects translation, and vice versa. By using the dual UTR technology, Vectron can optimize both transcription and translation irrespective of each other and as a result achieve much higher and predictable expression rates.

Read More
May 29, 2019
Vectron enters collaboration with Mycenax Biotech Inc.
Download PDF

Vectron enters non-exclusive collaboration with Mycenax Biotech Inc. to offer a superior and complete solution for microbial production of therapeutic proteins.

Through this agreement, Vectron and Mycenax will assist customers throughout the drug development process, from pre-clinical strain development to commercial manufacture. It combines the best of two worlds, state-of-the-art strain development for modern NBEs and biosimilars with cost-efficient manufacture from an experienced CMO with a great track record.

For more information please see the press release.

Read More
February 6, 2019
Vectron Biosolutions participated on this year's VIVO career day at NTNU
Download PDF

VIVO is a career fair for students studying Chemistry, Biology and Biotechnology.

As a company, we know that meeting these young people is a unique opportunity to create new pathways to the future.

Jostein Malmo in front of the Vectron Biosolutions' stand
Read More
February 4, 2019
Vectron receives Fab grant from NFR
Download PDF

A research grant for continued work on cost-efficient production of Fab therapeutic proteins has been received from NFR.

To build on exciting results and to further develop Vectron's expression technology platform for cost-efficient and robust production of Fabs and other antibody fragments, Vectron has received a substantial research grant from the Norwegian Research Council. The objective is to develop an expression platform that consistently result in >10 g/L of soluble Fabs. SINTEF will be project partner and utilize their extensive experience with fed-batch fermentation to help develop Fab production processes. The planned project is expected to start in the summer of 2019 and continue for four years.

Read More
December 20, 2018
Vectron signs license agreement with ArcticZymes
Download PDF

Vectron Biosolutions and ArcticZymes have entered a non-exclusive license agreement for recombinant expression of enzymes.

The two companies have collaborated on two projects and the results have shown a high success rate on a large set of target enzymes in ArcticZymes' discovery pipeline and high yields in scaled-up production processes. This agreement allows for more efficient discovery of new enzymes and improved yields in manufacturing of ArcticZymes' products.

Read More
July 24, 2018
Vectron is featured in Dagens Naeringsliv
Download PDF

Vectron Biosolution was featured in Dagens Naeringsliv on July 24, as one of the most interesting biotech startups in Norway.

Read More
September 18, 2017
In memoriam: Svein Valla
Download PDF

It is with great sadness we inform that Professor Svein Valla passed away on September 13 after a period of illness. As Professor at the Department of Biotechnology at NTNU, one of Svein's main research interests was protein synthesis in bacteria.

Through more than 40 publications in peer-reviewed journals, Svein greatly advanced our knowledge on the fundamental process of gene expression and protein synthesis in microorganisms. Almost as a byproduct of this basic research, Svein improved upon existing industrial tools for controlled production of proteins by developing an innovative new expression vector technology platform. To facilitate the commercialization of this technology, Svein took the initiative to founding Vectron Biosolutions and served as a Board member in the company for many years until his illness forced him to step down.

We remember Svein as a brilliant scientist with a great mind for details and overview. But even more, as a warm human being with various interests and a fantastic sense of humor.

Svein and co-founder Trond Erik in 2008

Read More
August 30, 2017
Vectron proud sponsor of the NTNU iGEM 2017 team
Download PDF

The iGEM 2017 team is a group of eight NTNU (Norwegian University of Science and Technology) students  working together on a research project where they aim to face the approaching challenge of antibiotics resistance by taking a closer look into the exciting area of phage-therapy.

Their goal is to develop an efficient way of selecting bacteriophages (a type of virus) for killing specific bacteria.

The team will present their achievements in Boston in November. Read more here.

Read More
March 30, 2017
New review paper of the XylS/Pm system
Download PDF

Gawin, Valla and Brautaset at NTNU, Norway, has recently published a comprehensive and great review of the XylS/Pm expression system. The paper is available over open access and can be read here.


Read More
November 11, 2016
Semifinal DNB Healthcare Prize 2016
Download PDF

Vectron has been selected for the semifinal in the DNB Healthcare Prize 2016 that will take place at the Oslo Cancer Cluster Incubator on November 17. The company will compete with other strong healthcare companies in a 6 minute pitch in front of a jury.


Read More
October 26, 2016
Vectron enters agreement with EnginZyme
Download PDF

After a successful feasibility study where Vectron's proprietary expression vector technology platform was used to develop a robust production process for the Candida antarctica CalB enzyme, Vectron and EnginZyme have today signed a license agreement.

EnginZyme AB is a Stockholm-based biocatalysis company and has now received the commercial rights to use Vectron's expression vector technology platform for manufacture of CalB for biocatalysis applications. This agreement includes the right to combine the CalB enzyme with EnginZyme's proprietary EziG immobilization matrix.

Read More
September 2, 2016
New advert for EBR
Download PDF

Our new advert that will be featured in the October and January issues of European Biopharmaceutical Review.

Read More
August 25, 2016
Dr. Jostein Malmo becomes Vectron's new CSO
Download PDF

Vectron is thrilled to announce that Dr. Jostein Malmo becomes the company's new CSO.

Read More
July 27, 2016
Carl-Aake Carlsson is appointed new Chairman
Download PDF

Carl-Aake Carlsson is appointed new Chairman of Vectron Biosolutions. The Board has also been strengthened by the additions of Tom Pike and Jan Håbrekke.

The company would like to thank Robert Wahren for his time in the Board. Robert has been with Vectron since the beginning and we wouldn't have been where we are today without his contributions.

Read More
July 13, 2016
Vectron is featured in Teknisk Ukeblad
Download PDF

Vectron was featured in the June issue of Teknisk Ukeblad. NTB made a release based on the TU article which was then picked up by many Norwegian newspapers, including Adressa and Fedrelandsvennen.

Read More
September 2, 2015
Vectron is featured in Adresseavisen
Download PDF

Vectron is featured in two articles in the Norwegian newspaper Adresseavisen.

Read More
Events

What’s coming up

News subscription
Stay up to date with our news, blog posts, and announcements by subscribing to our Newsletter.
Subscribe
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.